Research Article
Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico
Table 2
Comorbidities and mortality.
| | | Released alive | Decease | |
| | Sex | | | | | Men | 68% (28) | 31% (13) | | | Women | 68% (20) | 31% (9) | |
| | Comorbidities | | | | | Asthma | 100% (2) | 0% (0) | | | Diabetes mellitus | 73% (11) | 26% (4) | | | COPD | 0% (0) | 100% (1) | | | Obesity | 72% (16) | 27% (6) | | | Hypertension | 37% (6) | 62% (10) | | | CKD | 0% (0) | 100% (1) | | | Smoking | 50% (1) | 50% (1) | |
| | CO-RADS | | | | | CO-RADS 3 | 50% (3) | 50% (3) | | | CO-RADS 4 | 82% (19) | 17% (4) | | | CO-RADS 5 | 63% (26) | 36% (15) | | | Mechanical ventilation | 40% (9) | 59% (13) | |
|
|
